13617-98-6

Upstream product

• 554-00-7 2,4-Dichloroaniline 
• 110-46-3 isopentyl nitrite 

Downstream Products

• 53106-63-1 1-Chlor-1-cyano-3-(2,4-dichlorphenyl)-2,3-diaza-1-propen 
• 13123-92-7 (2,4-dichlorophenyl)hydrazine 
• 6574-98-7 2,4-dichlorobenzylnitrile 
• 120-82-1 1,2,4-Trichlorobenzene 
• 301223-42-7 2-amino-5-(2,4-dichlorobenzyl)-1,3-thiazole 
• 96423-50-6 N-(2,4-Dichloro-phenyl)-N'-(4,5-dihydro-thiazol-2-yl)-hydrazine; hydrobromide 
• 96406-71-2 N-(2,4-Dichloro-phenyl)-N'-(5,6-dihydro-4H-[1,3]thiazin-2-yl)-hydrazine; hydrochloride 
• 24095-98-5 C₈H₉Cl₂N₃S 
• 895582-70-4 ethyl 5-[4-(benzyloxy)phenyl]-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylate 
• 863639-49-0 C₂₆H₂₀Cl₂F₂N₂O₃ 
• 1021867-38-8 1-(2,4-dichlorophenyl)-5-{4-(5-methoxypentyl)phenyl}-4-methyl-1H-pyrazole-3-carboxylic acid 
• 168273-06-1 rimonabant 
• 168273-05-0 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl chloride 
• 162758-35-2 rimonabant acid 

Relevant academic research and scientific papers

(E)-N-Aryl-2-oxo-2-(3,4,5-trimethoxyphenyl)acetohydrazonoyl cyanides as tubulin polymerization inhibitors: Structure-based bioisosterism design, synthesis, biological evaluation, molecular docking and in silico ADME prediction

A series of (E)-N-Aryl-2-oxo-2-(3,4,5-trimethoxyphenyl)acetohydrazonoyl cyanides have been synthesized and evaluated for their anticancer activity in human hepatocellular liver carcinoma HepG2 and breast adenocarcinoma MCF-7 cell lines. Among all the test

Synthetic method of substituted phenyl diazene compound and application of synthetic method

The invention relates to a novel synthetic method of a substituted phenyl diazene compound and an application of the synthetic method. The substituted phenyl diazene compound is obtained through reduction of substituted phenyl diazonium salt; a reducing a

Synthesis method of substituted phenylhydrazine and salt thereof

The invention relates to a novel synthesis method of substituted phenylhydrazine and salt thereof. A substituted phenyl diazene compound is reduced to generate the substituted phenylhydrazine; a reducing agent B is selected from one or several of a catalytic hydrogenating system, formic acid, formate and formic acid ester compound; the obtained substituted phenylhydrazine can be further acidified to prepare the substituted phenylhydrazine salt which is easily stored and transported. The synthesis method has the advantages that the yield rate is high, the cost is low, the reaction time is short, the technology operation and post-treatment are simple, and the amount of waste water, waste gas and waste residue is fewer; the component of the produced waste water is single, the recycling is convenient, the treatment cost is low, and the green chemical requirement is met; the synthesis method of the substituted phenylhydrazine is more suitable for the large-scale industrialized production.

PYRAZOLE DERIVATIVES AS CBl MODULATORS

The present invention relates to compounds of formula (I) wherein R1 represents a group R5O- in which R5 represents a C3-7alkyl group substituted by one or more fluoro or R5 represents a C3-7alkylsulphonyl group which is optionally substituted by one or more fluoro; R2 represents a C1-4alkyl group, hydroxy, fluoro, chloro or cyano wherein each R2 is independently selected when n is >1; R3 represents a) cyclohexyl optionally substituted by one or more of the following: hydroxy, fluoro, amino, mono or diC1-3alkylamino, carboxy or a C1-4alkoxycarbonyl group b) piperidino substituted by one or more hydroxy c) unsubstituted piperidino but only when one of the following applies: R4 represents cyano or R1 represents 3-fluoropropylsulphonyloxy or R1 represents 3,3,3-trifluoropropoxy or R1 represents 3-fluoropropoxy or R2 is methyl d) phenyl substituted by one or more of the following: hydroxy, halo or a C1-4alkyl group e) pyridyl substituted by a C1-4alkyl group or f) a C4-9alkyl group; R4 represents cyano or methyl; and n is 1, 2 or 3 and pharmaceutically acceptable salts thereof and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS

Salts of 1,5-diarylpyrazole-3-carboxamides and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

4-Cyanopyrazole-3-carboxamide derivatives, preparation, and application thereof

The invention relates to 4-cyanopyrazole-3-carboxamide derivatives of formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8 are as described herein. Also disclosed and

THERAPEUTIC AGENTS

The present invention relates to 1,5-diphenylpyrazole compounds of formula I (A chemical formula should be inserted here - please see paper copy enclosed herewith) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A

The synthesis of the cannabinoid antagonist SR141716A is described from 4`-chloropropiophenone (1) in a four step sequence in an overall yield of 12 percent. The pharmacological results clearly demonstrate that SR141716A is able to antagonize the in vivo effects of the prototypical cannabinoid agonist Δ9-THC.

Antiimplantation Agents: Part I - 1-Arylthiosemicarbazides

Several 1-arylthiosemicarbazides, 2-arylhydrazinothiazolines and 2-arylhydrazinodihydrothiazines have been examined for their antiimplantation activity in rats.Among the active compounds, 4-methyl-1-(3,5-bistrifluoromethylphenyl)thiosemicarbazide (3, C 2696-Go) and the corresponding 4,4-dimethyl (47), ethyl (4), n-butyl (5) and allyl (6) derivatives completely inhibit implantation at doses 10, 3, 20, 20 and 30 mg/kg respectively.The 3,4-dichlorophenyl analogue (32) is effective at a dose of 30 mg/kg. 2-(3,5-Bistrifluoromethylphenyl)hydrazinothiazoline (51) and the corresponding dihydrothiazine (63) show a weaker activity.The biological profile of C 2696-Go has been investigated in detail.It appears to prevent implantation by its antiuterotropic activity and ability to inhibit desiduoma formation.